The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes
Table 1
Demographic and clinicopathologic characteristics of 143,184 AJCC stages 1–4 of first primary female invasive breast cancer from the California Cancer Registry 2000–2012.
White ( = 93,325)
Black ( = 8,718)
Hispanic ( = 24,078)
Asian/Pacific Islander ( = 16,476)
American Indian ( = 587)
Total = 143,184
Mean age in years ± SD
61.49 ± 13.47
57.72 ± 13.51
55.13 ± 13.35
55.87 ± 12.93
57.50 ± 12.44
59.53 ± 13.67
Age
45
12.1%
19.4%
25.5%
22.6%
16.5%
22,944
46–69
58.9%
59.9%
58.4%
61.1%
66.1%
84,704
70+
29.0%
20.7%
16.0%
16.2%
17.4%
35,536
AJCC stage
Stage 1
50.7%
37.1%
38.3%
45.0%
43.8%
67,435
Stage 2
37.1%
43.4%
42.8%
41.6%
38.3%
55,782
Stage 3
9.5%
14.5%
15.3%
10.6%
13.6%
15,664
Stage 4
2.7%
5.1%
3.6%
2.8%
4.3%
4,303
ER/PR/HER2 subtype
ER+/PR+/HER2−
61.3%
44.2%
52.2%
56.1%
56.9%
83,169
ER+/PR+/HER2+
8.7%
8.9%
10.3%
11.3%
9.5%
13,293
ER+/PR−/HER2−
9.7%
10.1%
8.7%
8.0%
9.7%
13,363
ER+/PR−/HER2+
3.0%
3.3%
3.4%
3.6%
3.6%
4,535
ER−/PR+/HER2−
0.7%
1.1%
1.0%
0.8%
0.7%
1,131
ER−/PR+/HER2+
0.3%
0.6%
0.6%
0.4%
0.2%
539
ER−/PR−/HER2−
11.2%
24.5%
15.9%
11.0%
14.0%
18,299
ER−/PR−/HER2+
5.2%
7.3%
7.9%
8.8%
5.5%
8,855
Socioeconomic status (SES)
SES1-low
6.6%
25.4%
28.0%
7.2%
18.4%
16,424
SES2
13.8%
24.9%
24.4%
14.3%
25.7%
23,383
SES3
20.2%
21.8%
20.1%
19.3%
26.1%
28,953
SES4
26.1%
17.6%
16.2%
26.9%
18.7%
34,332
SES5-high
33.3%
10.3%
11.4%
32.3%
11.1%
40,092
Tumor grade
Well differentiated; grade I (low)
25.6%
14.5%
16.9%
18.3%
20.3%
32,367
Moderately differentiated; grade II (low)
43.7%
35.1%
40.2%
43.0%
42.6%
60,820
Poorly differentiated; grade III (high)
29.5%
48.4%
41.1%
37.3%
36.1%
47,969
Undifferentiated; grade IV (high)
1.3%
2.0%
1.8%
1.3%
1.0%
2,028
Tumor size (mm)
1–4.99
6.3%
4.8%
5.0%
6.7%
5.6%
8,650
5.00–9.99
18.7%
12.0%
12.6%
14.5%
14.3%
23,968
10.00–19.99
38.6%
33.0%
34.2%
36.1%
35.8%
53,306
20.00–49.99
28.7%
36.9%
36.6%
34.0%
32.9%
44,623
50.00+
7.7%
13.3%
11.6%
8.6%
11.4%
12,637
includes cases with complete data for ER/PR/HER2, age, AJCC stage, tumor grade, tumor size, race/ethnicity, and socioeconomic status.
